The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

doi:10.21203/rs.3.rs-48446/v2

Download PDF

Research

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

https://doi.org/10.21203/rs.3.rs-48446/v2

This work is licensed under a CC BY 4.0 License

Journal Publication

published 17 Oct, 2020

Read the published version in Journal of Experimental & Clinical Cancer Research →

You are reading this older preprint version

Read the latest preprint version →

Background: Small cell lung cancer (SCLC) is a deadly neuroendocrine tumor with limited therapeutic options. Recent data suggest that histone deacetylases (HDACs) and the phosphatidylinositol 3-kinase (PI3K) pathway play essential roles in SCLC cell proliferation and survival.

Methods: The inhibition of the PI3K signaling and HDAC activity by CUDC-907 was analysized by western bloting. The effect of CUDC-907 on olaprib-induced DNA damage response was assessed by western blotting and Immunofluorescence staining. The cytotoxcity of CUDC-907 alone or in combination with olaparib in a panel of SCLC cell lines were evaluated by the CellTiter-Glo Luminescent Cell Viability Assay and flow cytometry. The in vivo effects of CUDC-907 and olaparib alone or in combination were examined using a patient-derived xenografts (PDX) model of SCLC.

Results: CUDC-907 treatment downregulated MYC paralogs and FoxM1, induced G1 cell-cycle arrest, and impaired DNA double-strand break (DSB) repair capacity in SCLC cells, which produced a potent antiproliferative effect. Furthermore, we showed that CUDC-907 treatment enhanced the therapeutic efficacy of PARP inhibitor olaparib in SCLC cellular models and a PDX model. Mechanistic investigations demonstrated that CUDC-907 synergized with olaparib through the blockade of DSB repair pathways and downregulation of MYC paralogs and FoxM1.

Conclusions: Our study uncovers that dual PI3K and HDAC inhibition by CUDC-907 exerts significant single-agent activity and strong synergistic effects with PARP inhibitor olaparib in SCLC, which thus provides a rational combination treatment strategy for SCLC clinical investigation.

Cancer Biology

SCLC

PI3K

HDAC

CUDC-907

PARP1

olaparib

DSB repair

Combination treatment

Small cell lung cancer (SCLC), which is characterized by rapid tumor growth and early metastasis, represents one of the deadliest cancer types among all solid tumor malignancies[1,2]. In the last couple of decades, the treatment landscape has not changed for SCLC and nearly all patients eventually develop resistance to previously effective therapies, leading to a five-year survival rate at less than 7% [3]. Although considerable efforts have been invested and encouraging results have been obtained in preclinical studies, there were no therapeutic breakthrough for this recalcitrant disease except the recent FDA approval of combined treatment using immunotherapy and chemotherapy [4]. Thus, developing effective targeted options is a pressing clinical need to improved therapeutic benefits for patients with SCLC

A growing body of evidence indicates that both genetic changes and epigenetic alterations are extensively correlated with cancer initiation and progression[5]. In contrast to genetic mutations, the dynamic and reversible nature of epigenetic modifications makes epigenetic enzymes attractive to be harnessed for cancer therapy. Several epigenetic drugs such as histone deacetylase (HDAC) inhibitors showed promising anticancer activity and have been approved as anticancer agents by the FDA for hematological malignancies[6-9]. Previous studies have shown HDACi, as single-agent or in combination with other small molecules, induces cell growth arrest, differentiation, and apoptosis in many cancer cell lines in vitro and in vivo, including SCLC [10-13].

Large-scale genomic and transcriptomic analyses have revealed that the PI3K/AKT/mTOR signaling pathway is frequently deregulated in SCLC[14-17], making it an attractive target for SCLC. We and others have demonstrated that therapeutic targeting of this oncogenic pathway achieved encouraging anticancer activity in SCLC[17,18]. However, acquired resistance to PI3K inhibitors is often developed due to concurrent activation of multiple oncogenic signaling networks. A potential strategy to overcome the resistance is to block the activation of those signaling pathways through histone deacetylase inhibition (HDACi). The combination of PI3K inhibitor with HDAC inhibitor has demonstrated promising anticancer effects in both preclinical and clinical studies in various cancers[19-22]. However, the combinatorial anticancer effect of the PI3K/AKT/mTOR pathway and HDAC inhibition has not been characterized in SCLC.

Poly ADP-ribose polymerase inhibitor (PARPi) has emerged as a promising anticancer agent in SCLC [23]. However, the efficacy of PARP inhibitors is limited by several mechanisms, including activation of homologous recombination (HR) and upregulation of the PI3K/AKT/mTOR pathway [24]. Thus, expanding the therapeutic potential of PARP inhibitors in SCLC is still an area of full interest. Herein, utilizing in vitro and in vivo models of SCLC, we explored the therapeutic merits of CUDC-907, a dual inhibitor of PI3K and HDAC. Furthermore, we set out to investigate whether CUDC-907 could improve the anticancer efficacy of PARP inhibitor olaparib through simultaneous, sustained disruption of the PI3K oncogenic pathway and DNA damage repair in SCLC.

Cell cultures and reagents

Human small cell lung cancer (SCLC) cell lines were kept in RPMI 1640 containing 10% fetal bovine serum and 1% penicillin/streptomycin(sangon biotech) at 37 °C in a humidified incubator with 5% CO2. RPMI-1640 media, FBS, and penicillin/streptomycin were purchased from Gibco, Life Technologies (Carlsbad, CA, USA). CUDC-907 was purchased from MedChemExpress (Monmouth Junction, NJ, USA). Olaparib was obtained from Selleck Chemical (Shanghai, China). The compounds were first dissolved in DMSO and then diluted in medium (Sigma-Aldrich, Saint Louis, MO, USA).

Cell viability assay

The small cell lung cancer cells were seeded into a 96-well dish in triplicates for each condition at an initial density of 3x10³ cells per well and cultured for 24 hours. The following day the cells were treated with increasing concentrations of CUDC-907 or olaparib alone or in combination for 72 hours. The cells were then harvested and analyzed using the CellTiter-Glo luminescent assay by following the manufacturer’s instructions. The IC50 values of CUDC-907 were calculated from the sigmoidal dose-response curve fits of data using the GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA, USA). Combination drug synergy was assessed using the CalcuSyn software (Biosoft) as previously described. In general, “CI<1” denotes synergism, whereas “CI>1” suggests antagonism [25].

Cell cycle and apoptosis

SCLC cells were treated with 10 nM CUDC-907 or 10 μM olaparib alone or in combination for 24 hours. After drug treatment, the cells were harvested and fixed by the dropwise addition of ice-cold EtOH. The fixed cells were stained with PI/RNase staining buffer (BD Biosciences, Franklin, NJ, USA), and then analyzed by a FACS Calibur (Sony Biotechnology, San Jose, CA, USA). The cell-cycle profiles were determined using ModFit software (Verity Software House, Topsham, ME, USA). To measure cell apoptosis, the cells were exposed to CUDC-907(10nM) or olaparib(10uM) alone or in combination for 48 hours following which Annexin assays were conducted by incubating cells with Annexin V–fluorescein isothiocyanate and propidium iodide. Cell apoptosis was analyzed by a FACS Calibur (CytExpert, Beckman Coulter, Brea, CA, USA) and the data was analyzed using FlowJo V10 software (FlowJo LLC, Ashland, Oregon, USA)

Western blotting and antibodies

Western blot samples were prepared as described previously[17]. Following treatment with 10 nM CUDC-907 or 10 μM olaparib alone or in combination for 24 hours, the cells were lysed in RIPA buffer containing protease and phosphatase inhibitors. The extracted proteins were then separated using SDS-PAGE and transferred to PVDF membranes after quantification using a BCA Protein Assay Kit. Antibodies against the following proteins were used in this study: Phospho-Akt (Ser473)(1:1000,CST,#9271), Akt (1:1000,CST,#9712), Phospho-4E-BP1 (Ser65) (1:1000,CST, #9456),4E-BP1(1:1000,CST,#9452), Phospho-S6 Ribosomal Protein (Ser235/236) (1:1000, CST, #4858 ), S6 Ribosomal Protein(1:1000, CST, #9202 ), acetyl-Histone H3（lys9）(1:1000, CST, #9649 ), PARP (1:1000, CST, #9542), Phospho-CHK1 (Ser317) (1:1000, CST, #12302), CHK1(1:1000, CST, #2360), p-DNA-PKcs (S2056) (Abcam, ab124918), DNA-PK(1:1000, Affinity, AF5340 ), p-RPA2/32 (Ser4/Ser8) (1:5000, Novus, NB100-544), RPA2/32(1:1000, Abcam,ab2175), c-MYC (1:1000, CST, #5605), N-MYC (1:1000, CST, #9405), γ-H2AX(1:1000, CST, #9718), Rad51 (1:10000, Abcam, ab133534), BCL-2(1:1000, CST, #4223), BCL-XL(1:1000, CST, #2764 ), BRCA1(1:1000, CST, #14823)，53BP1(1:1000, CST, #88436), FoxM1(1:1000, CST, #5436) and β-actin (1:10000, Transgen, HC201-02). Rabbit IgG (1:10,000, CST 7074) and mouse IgG (1:10,000, CST 7076) were used as secondary antibodies.

Immunofluorescence microscopy

Immunofluorescence staining was performed as described previously [23]. Both suspended and adherent cells were fixed onto glass using 1% paraformaldehyde. After blocking and permeabilizing, the cells were incubated with anti-γH2AX (1:500, CST, #2577) and anti-Rad51 (1:500, Abcam, ab133534), followed by a fluorophore-conjugated secondary antibody for 1 hour in a dark humidified chamber. After washing, the cells were counterstained using SlowFade Gold anti-fade reagent with DAPI (Invitrogen, Carlsbad, CA) and imaged using a Zeiss fluorescence microscope.

Comet assay

Comet assay was performed as previously described[26]. Briefly, the cells were inoculated in a 6-well plate. After 48 hours of CUDC-907(10 nM) or olaparib (10 μM) alone or combined treatment, the cells were collected and subjected to neutral single-cell gel electrophoresis. Following electrophoresis, the cells were stained with SYBR gold and viewed using a Zeiss fluorescence microscope.

Quantitative real-time PCR

The total RNA from each sample was isolated with Trizol reagent (Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s protocol. cDNA synthesis was synthesized by reverse transcription using cDNA Synthesis Kit (Roche, Mannheim, Germany). Q-PCR was performed using FastStart Essential DNA Green Master (vazyme, China) on a Roche LightCycler 96 Real-Time PCR System and following primers:

Rad51	Forward primer	5’-CAACCCATTTCACGGTTAGAGC-3’
Rad51	Reverse primer	5’-TTCTTTGGCGCATAGGCAACA-3’
MCM5	Forward primer	5’-ATGTCGGGATTCGACGATCCT-3’
MCM5	Reverse primer	5’-CCAGGTTGTAATGCCGCTTG-3’
CDC7	Forward primer	5’- GAGGCGTCTTTGGGGATTCAG-3’
CDC7	Reverse primer	5’-GGTCCTACTTGTAACTGTGCTG-3’
HK2	Forward primer	5’-GAGCCACCACTCACCCTACT-3’
	Reverse primer	5’-CCAGGCATTCGGCAATGTG-3’
LDHA	Forward primer	5’-ATGGCAACTCTAAAGGATCAGC-3’
LDHA	Reverse primer	5’-CCAACCCCAACAACTGTAATCT-3’
β-actin	Forward primer	5’-CATGTACGTTGCTATCCAGGC-3’
	Reverse prime	5’-CTCCTTAATGTCACGCACGAT-3’

Patients-derived-xenograft (PDX) mouse model of SCLC

Use of SCLC specimens was approved by the Ethics Committee of Hefei Institutes of Physical Science, Chinese Academy of Sciences, in accordance with the Declaration of Helsinki. Fresh SCLC Primary tumor tissues were collected and transferred to a sterile petri dish containing Medium 199 plus penicillin/streptomycin. Then the tumor was cut into 2×2×2 mm blocks. The tumor blocks were implanted into the subcutaneous fat pad spaces of nonobese diabetic/severe combined immunodeficient mice that were monitored for tumor to grow. For the drug treatment experiment, The 2 mm³ PDX tumor fragment were subcutaneously transplanted into the dorsal flanks of mice. When the tumor volume reached about 100mm³ in about two to three weeks, the mice were randomized into four groups and treated with DMSO control, CUDC-907, olaparib, and CUDC-907/olaparib combination for 15 days. For drug treatment, CUDC-907 was administrated to mice by oral gavage at a dose of 75 mg/kg/day. Olaparib was administrated to mice by intraperitoneal administration at a dose of 55 mg/kg/day. The tumor volume and weight of mice were measured every three days. Tumor sizes were measured using a caliper. Tumor weights were measured after 15 days of drug treatment. All mouse experiments were carried out according to a protocol approved by the Institutional Animal Care and Use Committee of Hefei Institutes of Physical Science. Female NOD/SCID (4–5-week old)) was purchased from Beijing Weitong Lihua Experimental Animal Limited Company.

Histological and immunohistochemical analyses

The tumor tissues were fixed overnight with 4% formalin, followed by dehydration and paraffin embedding. Histopathological analysis was performed out on 4-micrometer sections stained with hematoxylin and eosin. Immunohistochemical analyses were carried out according to the immunohistochemical (IHC) method described earlier [27]. Antibodies against the following proteins were used in this study: Ki67 (1:1000, CST #9449), Cleaved-Caspase 3 (1:300, CST, #9661), RAD51 (1:200, Abcam, ab133534) and γH2AX (Ser139) (1:500, CST, #2577), c-myc (1:500, abcam, ab32072). Four to five random 40X fields were scored for each tumor sample. The staining intensity was quantified as the percentage of nuclear positive cells.

Quantification and statistical analysis

The quantitative results were analyzed by double-tailed unpaired t-test using GraphPad Prism version 7.00 for Mac GraphPad Software. For in vitro analytical experiments, each test was repeated at least three times, with experiments being performed at least twice. Error bars for SD or SEM are shown. Where indicated in the figures, degrees of p-value significance are as follows: *p < 0.05, **p < 0.01, ***p < 0.001.

Small cell lung cancer cells are highly sensitive to dual HDAC and PI3K inhibitor CUDC-907

As the PI3K signaling pathway and HDAC both are commonly dysregulated in SCLC cells, we wondered whether dual inhibition of phosphoinositide 3-kinase class I and pan histone deacetylase enzymes is effective in treating SCLC cells. A panel of SCLC cells was treated with increased concentrations of CUDC-907, a dual inhibitor of PI3K and HDAC, and the growth inhibitory effect of CUDC-907 was measured by CellTiter Glo assay after 3 days. We found that SCLC cells were highly sensitive to CUDC-907, with half-maximal inhibitory concentration (IC50) values at low nanomolar levels in all of SCLC cell lines examined (Fig. 1A). We then evaluated the effect of CUDC-907 on cell cycle progression by flow cytometry. CUDC-907 induced dose-dependent G1/S arrest in all of SCLC cell lines examined (Fig. 1B). Concordantly, p21, a key cell cycle regulator, was significantly induced by CUDC-907 (Fig. 1C). We also assessed the ability of CUDC-907 to induce apoptosis by western blotting. CUDC-907 treatment resulted in a dose-dependent accumulation of PARP cleavage in the cell lines tested (Fig. 1D). Together, these results suggest that CUDC-907 may exhibit potent cellular cytotoxicity against SCLC cells in part through cell cycle arrest and/or inducing cell apoptosis.

We then sought to investigate the mechanisms underlying the growth inhibitory effect of CUDC-907 as single-agent in SCLC. We evaluated the changes induced by CUDC-907 in protein markers related to the PI3K pathways and HDAC. As expected, we observed that CUDC-907 inhibited the PI3K pathway, as indicated by the dose-dependent decreases in phosphorylation of AKT and its downstream targets, p-4EBP-1, and p-S6RP in all SCLC cell lines tested (Fig.1D & Supplementary Fig.1). Meanwhile, the acetylation histone 3 was robustly induced by CUDC-907 in a dose-dependent fashion, consistent with its effect as a histone deacetylase inhibitor (Fig.1D). Together, we demonstrate that dual inhibition of PI3K and HDAC by CUDC-907 exhibits significantly enhanced anticancer activity against SCLC cells.

CUDC-907 downregulates MYC signaling

Previous studies showed that CUDC-907 and other HDAC inhibitors suppress MYC expression and inhibit MYC-dependent tumor proliferation in a variety of cancer types[20,21,28]. First, the expression of MYC paralogs was determined by western blot in a panel of SCLC cell lines. Western blot analysis showed that five cell lines (DMS273, H82, H526, H69, and H446) have high expression level of c-MYC or MYCN and two cell lines (DMS79 and SHP77) have low or modest c-MYC expression, respectively (Fig.2A). We next examined whether CUDC-907 treatment reduced the expression of Myc paralogs in SCLC. SCLC cell lines harboring either c-MYC or MYCN amplification were treated with increased concentrations of CUDC-907(Fig. 2B). Consistent with its potent effect in inhibiting the growth of cell lines with MYC alteration, western blot analysis showed that the abundance of c-MYC and MYCN were significantly reduced by CUDC-907 in a dose-dependent manner (Fig. 2B). Furthermore, the expression of MYC downstream targets, including LDHA, HK2, MCM5, and CDC7 was markedly reduced upon CUDC-907 or CUDC-907 combined with olaparib treatment in MYC paralog-amplified or overexpressed SCLC cells and tumors (Supplementary Fig.2 & Supplementary Fig.5).. Together, these data indicate that CUDC-907 effectively downregulates MYC signaling in SCLC, which might be partially attributable to the inhibitory effects of CUDC-907 in SCLC cell lines.

Dual inhibition of PI3K and HDAC by CUDC-907 hampers DSB repair activity

Given the roles of HDAC and PI3K inhibitors in DNA damage repair, we evaluated the effect of CUDC-907 on DNA damage in SCLC cells. Western blot analysis revealed that treatment with CUDC-907 resulted in a dose-dependent increase of γH2AX, a marker of DNA double-strand breaks (DSBs) (Fig. 2C & Supplementary Fig.4), indicating that CUDC-907 as monotherapy induced DNA damage in SCLC cells.

As CUDC-907 treatment induced dose-dependent accumulation of DNA DSB damage, we next sought to explore the effects of CUDC-907 on DSB repair pathways. CUDC-907 treatment resulted in significantly decreased Rad51 expression (Fig. 2C & Supplementary Fig.3), reflecting compromised HR activity after CUDC-907 treatment. Furthermore, we wondered whether CUDC-907 treatment had an effect on the NHEJ repair pathway, another important DSB repair pathway that functions throughout the whole cell cycle. Interestingly, we found that CUDC-907 treatment resulted in significantly increased expression of phosphorylated DNA-PKcs at 2056 sites even though the expression of DNA-PKcs was markedly reduced (Fig. 2C & Supplementary Fig.4), indicating decreased DNA end resection following CUDC-907 treatment. Together, our results indicate that CDUC907 as single-agent induces DNA damage and decreases DNA damage repair activity in SCLC cells.

CUDC-907 potentiates the effect of PARP inhibitor olaparib in SCLC PARP inhibitor, as a promising anticancer agent, has shown encouraging efficacy in SCLC. However, PARP inhibitor efficacy is limited by several factors, such as PI3K activity and HR status [24]. Based on the aforementioned finding, we hypothesized that CUDC-907 would synergize with olaparib to potentiate the anticancer effect of olaparib in SCLC cells. To test this possibility, we treated a panel of SCLC cell lines with increasing concentration of CUDC-907 and olaparib as single-agents or in combination. The combined use of CUDC-907 and olaparib resulted in combination indexes (CI) of less than 1 in all of the concentrations tested in the SCLC cell lines examined (Fig. 3A), indicating a strong synergistic effect of CUDC-907 and olaparib on these SCLC cell lines.

To determine the effect of combined use of CUDC-907 and olaparib on cell apoptosis, apoptosis assay was conducted by Annexin V staining in SCLC cell lines. While CUDC-907 alone induced cell apoptosis to some extent, the apoptotic effect was further augmented by olaparib (Fig. 3B). In support of the results of flow cytometry, accumulation of PARP cleavage was observed in CUDC-907 treated cells, and to an even more significant extent, in cells treated with combined CUDC-907 and olaparib (Fig. 3C). Similarly, a substantial accumulation of caspase-3 cleavage was observed after combined treatment with CUDC-907 and olaparib (Fig. 3C).Together, these data indicate that CUDC-907 enhances cell apoptosis induced by olaparib and sensitize SCLC cells to olaparib.

Combination of CUDC-907 and olaparib sufficiently enhances DNA damage

To dissect the synergistic anti-tumor mechanism of CUDC-907 and olaparib in SCLC cells, we evaluated the extent of DNA damage upon CUDC-907 as single-agent treatment and in combination with olaparib. CUDC-907 combined with olaparib significantly increased the expression levels of γH2AX than CUDC-907 alone (Fig. 3C). We then examined the extent of DNA damage using comet assay. In the single-agent treatment arm, SCLC cells displayed DSBs to some degree in six SCLC cells examined, while the combination arm led to a remarkable accumulation of DNA in the tail, reflecting more severe DNA DSBs upon the combination treatment (Fig. 4A). In support of the comet assay results, immunofluorescence assay in six SCLC cell lines further confirmed much more elevated γH2AX foci in cells treated with the combination of CUDC-907 and olaparib than those treated with either drug alone (Fig. 4B). These results indicate that CUDC-907, in combination with olaparib, leads to a synergistic effect on DNA damage in SCLC.

Combining CUDC-907 and olaparib attenuates DNA damage repair

To further discern the synergistic effect of CUDC-907 and olaparib on DNA damage in SCLC cells, we aimed to assess the impact of drug treatment on DNA damage repair activity. Immunofluorescence staining was performed to examine Rad51 foci formation, As expected, the formation of Rad51 nuclear foci was remarkably induced by olaparib, while CUDC-907 remarkably reduced olaparib-induced Rad51 foci in SCLC cell lines examined, suggesting impaired HR repair as a result of combined use of CUDC-907 and olaparib (Fig. 5A). To further explore whether CUDC-907 treatment led to impaired HR repair genes transcription, we conducted quantitative real-time PCR and western blot. We found that CUDC-907 significantly reduced the basal and olaparib-induced Rad51 expression, indicating that CUDC-907 reduced Rad51 expression through inhibition of RAD51 transcription (Fig. 5B and Supplementary Fig. 3). It is well documented that the ATR-CHK1 pathway is activated in response to DNA damage. Western blot analysis showed that olaparib substantially induced the p-CHK1 expression, which was counteracted by CUDC-907 in SCLC cells (Fig. 5B & Supplementary Fig.6).

Nonhomologous end-joining (NHEJ) is another DSB repair pathway that requires 53BP1, Ku70/80 complex, and other c-NHEJ factors like DNA-PKcs in mammalian cells. To determine the effect of CUDC-907 treatment on NHEJ, SCLC cells were treated with CUDC-907 as single-agent or in combination with olaparib for 24 hours. Western blot analysis showed that CUDC-907 as single-agent or in combination with olaparib significantly reduced 53BP1 expression (Fig. 5B), indicating decreased activity of DNA damage repair following CUD-907 treatment . Evaluation of NHEJ revealed that SCLC cells treated with CUDC-907 alone or combined with olaparib showed significantly decreased KU80 expression compared with the vehicle or olaparib-treated group(Fig. 5B). Furthermore, CUDC-907 as monotherapy or combined with olaparib remarkably enhanced p-DNA-PKcs (Fig. 5B & Supplementary Fig.6).

Given that both MYC and FoxM1 regulate the genes that control DSB repair, we decided to check the expression of MYC paralogs and FoxM1 upon drug treatment. In accord with the observation shown in Fig. 2B, CUDC-907 treatment downregulated the expression of either c-MYC or N-MYC (Fig. 5C). Interestingly, FoxM1 expression was markedly induced in several cell lines examined (H69, H526, DMS273, and DMS79) following olaparib treatment. The addition of CUDC-907 could downregulate FoxM1 expression induced by olaparib (Fig. 5C). Taken together, these results suggest that CDUC907 treatment resulted in function defects in HR and NHEJ, which might be due to the downregulation of MYC paralogs and FoxM1.

The combined use of CUDC-907 and olaparib effectively suppresses tumor growth in a PDX model of SCLC

We next evaluated the efficacy of CUDC-907 and olaparib as single-agents or in combination in SCLC in a PDX model of SCLC with MYC overexpression (Supplementary Fig.7). No significant difference in body weight between control and treated mice was observed (Data not show), indicating that CUDC-907 monotherapy or in combination with olaparib is well tolerated. While olaparib as monotherapy showed limited efficacy, CUDC-907-treated mice exhibited stronger tumor growth inhibition as compared to vehicle-treated mice. Remarkably, the combination of CUDC-907 and olaparib resulted in a stronger antitumor efficacy in tumor-bearing mice than either single-agent treatment group (Fig. 6A & 6B). To better understand the mechanism whereby CUDC-907 and olaparib cooperate to inhibit tumor growth, immunohistochemistry (IHC) analysis was performed on the tumor tissues treated with olaparib, CUDC-907 or a combination of these two drugs. In comparison with single-agent treated groups, the combined use of CUDC-907 and olaparib caused substantially decreased ki67 and increased cleaved-caspase3 staining positive cells (Fig. 6C). Concordantly, further IHC analysis of tumor tissues showed significantly reduced expression of HR repair protein Rad51 and c-NHEJ factor KU80 in the combination group compared with single-agent alone (Fig. 6C), indicating accumulation of DNA double-strand breaks due to attenuated DSB repair activity upon a CUDC-907 and olaparib combination. Moreover, the MYC expression was significantly reduced in CUDC-907 or the combination-treated arms (Fig. 6C) and the expression of MYC targets was markedly suppressed (Supplementary Fig. 5), which was consistent with the results observed in cell lines. Together, our data suggest that a combination of CUDC-907 and olaparib displays synergistic antitumor effects in a PDX model of SCLC.

Small cell lung cancer is a fatal neuroendocrine carcinoma with no effective targeted therapy. Despite the recent advance in the identification of novel therapeutic targets for SCLC, single-target drugs have been met with limitations. Therefore, multiple-target drugs might be an attractive avenue to increase cancer treatment effectiveness and sometimes decrease systemic toxicity. Although the dose of single-target HDAC or PI3K inhibitor can be adjusted to treat cancer, single-target drugs might cause serious adverse events or lead to resistance. Interestingly, the combination of these two inhibitors could generate synergistic effect to inhibit tumor growth in vivo [20]. More importantly, CUDC-907 has been proved well tolerated. Therefore simultaneous inhibition of two pathways by CUDC-907 could be more effective than HDAC or PI3K inhibitor alone. The current study demonstrated that dual inhibition of PI3K and HDAC by CUDC-907 had potential anti-tumor efficacy in SCLC. Mechanistic investigations showed CUDC-907 induced cell cycle arrest and apoptosis, inhibited MYC and FoxM1, decreased DNA damage repair activity in SCLC cells. Most importantly, the study further showed that CUDC-907 potentiated the efficacy of PARP inhibitor olaparib in SCLC. The combined use of CUDC-907 and olaparib had a greater therapeutic efficacy against SCLC compared with either treatment alone.

The frequent activation of the PI3K/AKT/mTOR pathway has been demonstrated by several studies in both SCLC cell lines and clinical specimens[16,29,30,31]. Targeting the PI3K/AKT/mTOR signaling has shown potent treatment effects in SCLC cell lines. However, a preclinical study showed that PI3K inhibitor is effective in treating PIK3CA mutated, but not PTEN-deficient endometrial cells, thus limiting the efficacy of PI3K inhibitor as monotherapy[26]. Also, a previous clinical phase ‖ study indicated that mTOR inhibitor was not effective against SCLC [32]. Therefore, these studies demonstrated that identifying multiple-targeted drugs may expand treatment effects. CUDC-907, a dual inhibitor of PI3K and HDAC that targeting class Ɩ PI3Ks as well as class Ɩ and class ‖ HDAC has shown remarkable anti-tumor efficacy in multiple cancer types [20,21,22,33]. However, the effect of CUDC-907 has not been investigated in SCLC. The current study demonstrated that CUDC-907 has strong antiproliferative effects in SCLC. Moreover, we showed that CUDC-907 strongly enhanced the effects of PARP inhibitor in SCLC. Our investigation provides a mechanistic demonstration for the efficacy of CUDC-907 single-agent activity and provides a rational combination modality for SCLC.

Transcriptomic analyses indicate that DNA damage repair genes are highly expressed in SCLC, limiting the efficacy of PARP inhibitors and other DNA-damaging agents. CUDC-907 showed strong activity to reduce the expression of crucial NHEJ and HR factors, including RAD51, KU80, 53BP1, which provides the rationale to combine CUDC-907 with those DNA-damaging agents for the treatment of SCLC. A recent study showed that CUDC-907 reduces DDR-related gene expression through suppressing transcription factor FoxM1-mediated transcription [33]. The current study showed that CUDC-907 treatment significantly inhibits the expression of FoxM1 and MYC paralogs, two transcription factors frequently amplified or overexpressed in SCLC cells. Both FoxM1 and MYC paralogs can directly regulate the expression of DDR genes [33.34]. Our data indicate that CUDC-907 might decrease DDR gene expression through the downregulation of FoxM1 and MYC paralogs.

MYC paralogs are exclusively amplified or overexpressed in SCLC, leading to treatment resistance. We showed that CUDC-907 treatment resulted in a dose-dependent downregulation of MYC paralogs in a panel of SCLC cell lines. Furthermore, our results also showed that the downstream targets of MYC signaling were inhibited by CUDC-907 treatment. Therefore, MYC itself and its downstream signaling besides DDR pathways at least partially contribute to the antitumor effects of CUDC-907.

PARP inhibitors represent the most anticipated anti-tumor drugs for SCLC [23]. The current study indicated that CUDC-907 treatment led to decreased HR factor Rad51 and NHEJ factor KU80 and 53BP1, indicating that targeting DSB repair pathways with dual HDAC-PI3K inhibitors is a promising strategy to improve PARPi efficacy in SCLC. Beyond the existing mechanism of CUDC-907 that present in this manuscript, more mechanistic investigations are needed to support the potential utility of this combination in the treatment of SCLC. Nonetheless, this study demonstrates the single-agent activity of CUDC-907 in SCLC, and most importantly, establishes the therapeutic rationale for the combination of dual HDAC-PI3K inhibitors and olaparib in SCLC. Our study may provide a new combination strategy for further SCLC clinical investigation.

The current study demonstrated that dual inhibition of PI3K and HDAC by CUDC-907 had potential anti-tumor efficacy in SCLC. Mechanistic investigations showed CUDC-907 induced cell cycle arrest and apoptosis, inhibited MYC and FoxM1, decreased DNA damage repair activity in SCLC cells. Most importantly, the study further showed that CUDC-907 potentiated the efficacy of PARP inhibitor olaparib in SCLC. The combined use of CUDC-907 and olaparib had a greater therapeutic efficacy against SCLC compared with either treatment alone.The current study indicated that CUDC-907 treatment led to decreased HR factor Rad51 and NHEJ factor KU80 and 53BP1, indicating that targeting DSB repair pathways with dual HDAC-PI3K inhibitors is a promising strategy to improve PARPi efficacy in SCLC.

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Hefei Institutes of Physical Science, Chinese Academy of Sciences.

Consent for publication

Not applicable

Competing interests

The authors declare no competing interests

Funding

This study was supported by National Natural Science Foundation of China (Grant Numbers: 81972191 and 81672647), Science and Technology Major Project of Anhui Province (Grant Number: 18030801140), Key program of 13th five-year plan of CASHIPS (Grant Number: KP-2017-26), and the 100-Talent Program of Chinese Academy of Sciences. A portion of this work was supported by the High Magnetic Field Laboratory of Anhui Province.

Authors’ contributions

WCL and XB conceived and designed the study and wrote the manuscript. LYM performed the experiments and collected data. The author(s) read and approved the final manuscript.

Acknowledgements

We thank members of the Lin laboratory for critical reading of the manuscript and helpful discussions.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

References:

[1] A.F. Gazdar, P.A. Bunn, J.D. Minna, Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17 (2017) 725-737.

[2] J.K. Sabari, B.H. Lok, J.H. Laird, J.T. Poirier, C.M. Rudin, Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14 (2017) 549-561.

[3] M.C. Pietanza, L.A. Byers, J.D. Minna, C.M. Rudin, Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res 21 (2015) 2244-55.

[4] L. Horn, A.S. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M.J. Hochmair, et al., First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 379 (2018) 2220-2229.

[5] S.B. Baylin, P.A. Jones, Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 8 (2016).

[6] B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, R. Pazdur, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 (2007) 1247-52.

[7] C. Grant, F. Rahman, R. Piekarz, C. Peer, R. Frye, R.W. Robey, et al., Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 10 (2010) 997-1008.

[8] A. Sawas, D. Radeski, O.A. O'Connor, Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol 6 (2015) 202-8.

[9] D. Moore, Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma. P T 41 (2016) 296-300.

[10] Y. Zhang, M. Adachi, X. Zhao, R. Kawamura, K. Imai, Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer 110 (2004) 301-8.

[11] S. Doi, H. Soda, M. Oka, J. Tsurutani, T. Kitazaki, Y. Nakamura, et al., The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 3 (2004) 1397-402.

[12] M.C. Crisanti, A.F. Wallace, V. Kapoor, F. Vandermeers, M.L. Dowling, L.P. Pereira, et al., The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 8 (2009) 2221-31.

[13] K. Ha, W. Fiskus, D.S. Choi, S. Bhaskara, L. Cerchietti, S.G. Devaraj, et al., Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 5 (2014) 5637-50.

[14] S. Umemura, S. Mimaki, H. Makinoshima, S. Tada, G. Ishii, H. Ohmatsu, et al., Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol 9 (2014) 1324-31.

[15] J.S. Ross, K. Wang, O.R. Elkadi, A. Tarasen, L. Foulke, C.E. Sheehan, et al., Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 67 (2014) 772-6.

[16] J. George, J.S. Lim, S.J. Jang, Y. Cun, L. Ozretic, G. Kong, et al., Comprehensive genomic profiles of small cell lung cancer. Nature 524 (2015) 47-53.

[17] B. Hong, H. Wang, K. Deng, W. Wang, H. Dai, L.V. Yan, et al., Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer. Oncotarget 8 (2017) 106486-106498.

[18] H. Makinoshima, S. Umemura, A. Suzuki, H. Nakanishi, A. Maruyama, H. Udagawa, et al., Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma. Cancer Res 78 (2018) 2179-2190.

[19] M. Mosleh, A. Safaroghli-Azar, D. Bashash, Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance. Int J Biochem Cell Biol 122 (2020) 105734.

[20] Y. Pei, K.W. Liu, J. Wang, A. Garancher, R. Tao, L.A. Esparza, et al., HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. Cancer Cell 29 (2016) 311-323.

[21] K. Sun, R. Atoyan, M.A. Borek, S. Dellarocca, M.E. Samson, A.W. Ma, et al., Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers. Mol Cancer Ther 16 (2017) 285-299.

[22] S. Kotian, L. Zhang, M. Boufraqech, K. Gaskins, S.K. Gara, M. Quezado, et al., Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases. Clin Cancer Res 23 (2017) 5044-5054.

[23] L.A. Byers, J. Wang, M.B. Nilsson, J. Fujimoto, P. Saintigny, J. Yordy, et al., Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2 (2012) 798-811.

[24] R.J. Cardnell, L.A. Byers, Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--response. Clin Cancer Res 20 (2014) 2237.

[25] X. Liu, W. Wang, Y. Yin, M. Li, H. Li, H. Xiang, et al., A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer. Invest New Drugs 37 (2019) 1166-1176.

[26] X. Bian, J. Gao, F. Luo, C. Rui, T. Zheng, D. Wang, et al., PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37 (2018) 341-351.

[27] W. Lin, J.M. Francis, H. Li, X. Gao, C.S. Pedamallu, P. Ernst, et al., Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets. Cancer Biol Ther 17 (2016) 1274-1281.

[28] S.V. Hegarty, K.L. Togher, E. O'Leary, F. Solger, A.M. Sullivan, G.W. O'Keeffe, Romidepsin induces caspase-dependent cell death in human neuroblastoma cells. Neurosci Lett 653 (2017) 12-18.

[29] S. Umemura, S. Mimaki, H. Makinoshima, S. Tada, G. Ishii, H. Ohmatsu, et al., Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol 9 (2014) 1324-31.

[30] J.S. Ross, K. Wang, O.R. Elkadi, A. Tarasen, L. Foulke, C.E. Sheehan, et al., Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 67 (2014) 772-6.

[31] B. Hong, H. Wang, K. Deng, W. Wang, H. Dai, L.V. Yan, et al., Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer. Oncotarget 8 (2017) 106486-106498.

[32] A. Tarhini, A. Kotsakis, W. Gooding, Y. Shuai, D. Petro, D. Friedland, et al., Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 16 (2010) 5900-7.

[33] S. Pal, D. Kozono, X. Yang, W. Fendler, W. Fitts, J. Ni, et al., Dual HDAC and PI3K Inhibition Abrogates NFkappaB- and FOXM1-Mediated DNA Damage Response to Radiosensitize

[34] K.R. Luoto, A.X. Meng, A.R. Wasylishen, H. Zhao, C.L. Coackley, L.Z. Penn, et al., Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res 70 (2010) 8748-59.

SCLC: small cell lung cancer; HDAC: histone deacetylase; PI-3K: phosphatidylinositol 3 kinase; PDX: patient-derived xenografts; SCLC: Small cell lung cancer: DSB: DNA double-strand break; HR: homologous recombination; PARPi: Poly ADP-ribose polymerase inhibitor; NHEJ: Nonhomologous end-joining; RAD51: RAD51 recombinase; IC50: Inhibitory concentration; p-AKT: Phosphorylated-AKT; p-DNAPK: Phosphorylated-DNA-dependent protein kinase; PARP: Poly ADP-ribose polymerase; IHC: immunohistochemical; FoxM1: forkhead box M1

Download PDF

Journal Publication

published 17 Oct, 2020

Read the published version in Journal of Experimental & Clinical Cancer Research →

Review #2 received at journal
30 Sep, 2020
Editorial decision: Minor revision
30 Sep, 2020
Reviewer #2 agreed at journal
24 Sep, 2020
Review #1 received at journal
24 Sep, 2020
Editor assigned by journal
23 Sep, 2020
Reviewers invited by journal
23 Sep, 2020
Reviewer #1 agreed at journal
23 Sep, 2020
Submission checks completed at journal
22 Sep, 2020
Editor invited by journal
22 Sep, 2020

You are reading this older preprint version

Read the latest preprint version →

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Status:

Journal Publication

Version 2

Abstract

Figures

Background

Materials And Methods

Results

Discussion

Conclusion

Declarations

Acknowledgements

References

Abbreviations

Supplementary Files

Status:

Journal Publication

Version 2